Canopy Growth Corp T.WEED

Alternate Symbol(s): T.WEED.DB | CGC

Healthcare Cannabis

Canopy Growth Corporation is a cannabis company. It delivers innovative products with a focus on premium and mainstream cannabis brands, including Doja, 7ACRES, Tweed, and Deep Space, in addition to category-defining vaporizer technology made in Germany by Storz & Bickel. The principal activities of the Company are the production, distribution and sale of a diverse range of cannabis and cannabinoid-based products for both adult-use and medical purposes under a portfolio of distinct brands in Canada. Its Canada cannabis segment includes the production, distribution, and sale of a range of cannabis, hemp, and cannabis related products in Canada. International markets cannabis segment includes the production, distribution, and sale of a range of cannabis and hemp products internationally. Storz & Bickel segment includes the production, distribution, and sale of vaporizers. This Works segment includes the production, distribution and sale of beauty, skincare, wellness and sleep products.

TSX:WEED - Post by User

Canopy Growth Corp > Couple of cheerful days

<< Previous

Bullboard Posts

Next >>

Comment by Homestretch4meon Sep 24, 2021 9:49am

96 Views

Post# 33913416

RE:Couple of cheerful days

There he is..........and that confirms the bottom is near. Good morning Lou(ser)

lou64 wrote: Suck those that believe things are turning around ... much more negativity will happen before any turn around in the Weed sector ... watch the quarterly ....

you people did not care to listen or visualize the writing of this sector which was built on pure hype and over zealous investors

2021-09-24 07:55 ET - In the News

The Globe and Mail reports in its Friday, Sept. 24, edition that CIBC analyst John Zamparo is keeping his "neutral" recommendation for Canopy Growth intact. The Globe's David Leeder writes in the Eye On Equities column that Mr. Zamparo says the 25-per-cent decline as measured by sector ETFs over the past three months resulted from a "lack of profitability from most Canadian [pot] producers, the continued dearth of institutional investors and the realization that U.S. legalization appears unlikely until at least next year." Mr. Zamparo cut his share target by $5 to $22. Analysts on average target the shares at $27.18. Mr. Zamparo says in a note: "We have lowered our FQ2 sales and EBITDA forecasts for Canopy following the CEO's statement at a recent conference that year-over-year sales may decline in the quarter. Since FQ2 last year, Canopy has gained $15- to $20-million in quarterly revenue from acquisitions, implying that core revenue declined double digits year-over-year in a quarter in which stores operated unrestricted. We estimate that same-store sales were likely down 20 per cent year-over-year owing to the saturated Ontario retail environment, as well as a 3 to 4 percentage point decline in market share."

© 2021 Canjex Publishing Ltd. All rights reserved.